Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1998;29:743-749

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aichner, F. T.
Right arrow Articles by Zeiler, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aichner, F. T.
Right arrow Articles by Zeiler, K.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Transient Ischemic Attack

(Stroke. 1998;29:743-749.)
© 1998 American Heart Association, Inc.


Original Contributions

Hypervolemic Hemodilution in Acute Ischemic Stroke

The Multicenter Austrian Hemodilution Stroke Trial (MAHST)

Franz T. Aichner, MD; Franz Fazekas, MD; Michael Brainin, MD; Werner Pölz, PhD; Bruno Mamoli, MD; Karl Zeiler, MD

From the Department of Neurology and MR Institute, Leopold Franzens University Innsbruck (F.T.A.); Department of Neurology, Karl Franzens University, Graz (F.Z.); Neurological Clinic, Maria Gugging (M.B.); Institute of System Sciences, Johannes Kepler University (W.P.), Linz; 2nd Neurological Clinic, Rosenhügel (B.M.), Vienna; and Department of Neurology, Alma Mater Rudolfina, Vienna (K.Z.), Austria.

Correspondence to Franz T. Aichner, MD, Department of Neurology and Magnetic Resonance, University Hospital, Anichstraße 35, 6020 Innsbruck, Austria. E-mail mri-institut{at}uibk.ac.at

Background and Purpose—Experimental studies suggest a beneficial effect of hemodilution on acute ischemic stroke. This was not proven by previous multicenter trials in the clinical setting. Various reasons have been suggested for the failure of these studies, which we attempted to consider in the Multicenter Austrian Hemodilution Stroke Trial (MAHST).

Methods—MAHST is a randomized, double-blind, placebo-controlled study of hypervolemic hemodilution (HHD) within 6 hours of a clinically first ischemic stroke localized in the middle cerebral artery territory. The treatment consisted of 10% hydroxyethyl starch 200/0.5 (HES) and was tested against pure rehydration with Ringer's lactate over a period of 5 days. Our primary outcome measure was clinical improvement within 7 days as measured by the Graded Neurologic Scale (GNS). We performed an adaptive interim analysis to reevaluate the study goal after entering half of the projected number of patients (n=200). At least 600 patients per group would have been required for significant results, and therefore we decided to terminate the trial.

Results—Ninety-eight patients received HHD and 102 patients placebo. The baseline characteristics were comparable between both groups. In the HHD group the absolute reduction of the hematocrit was 2.5% on day 2 with a maximum of 3.7% on day 5, which compares with a reduction in the placebo group of 1% and 1.9%, respectively. Intention-to-treat analysis showed no significant difference of the change of the GNS scores between HHD-treated (median, -8.5; 95% confidence interval, -14.2 to -4.0) and placebo-treated patients (median, -6.0; 95% confidence interval, -11.0 to 0.0) on day 7, and GNS scores remained similar in both treatment groups throughout the trial. At 3 months, slightly more HHD patients showed complete independence on the Barthel Index (28 versus 24), and fewer HHD than placebo patients had died (13 versus 17), but these differences were not statistically significant. HHD treatment was not associated with any specific adverse event.

Conclusions—Mild HHD is safe but failed to demonstrate a significant beneficial effect over the pure rehydration regimen in patients with acute ischemic stroke.


Key Words: clinical trials • hemodilution • hydroxyethyl starch • stroke, ischemic




This article has been cited by other articles:


Home page
CirculationHome page
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al.
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Circulation, May 22, 2007; 115(20): e478 - e534.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al.
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists
Stroke, May 1, 2007; 38(5): 1655 - 1711.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
E. Ruttmann, J. Willeit, H. Ulmer, O. Chevtchik, D. Hofer, W. Poewe, G. Laufer, and L. C. Muller
Neurological Outcome of Septic Cardioembolic Stroke After Infective Endocarditis
Stroke, August 1, 2006; 37(8): 2094 - 2099.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
Evidence-based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement
Am. J. Respir. Crit. Care Med., December 1, 2004; 170(11): 1247 - 1259.
[Full Text] [PDF]


Home page
StrokeHome page
C. S. Weaver, J. Leonardi-Bee, F. J. Bath-Hextall, and P. M.W. Bath
Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome
Stroke, May 1, 2004; 35(5): 1216 - 1224.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. Uchino, D. Billheimer, and S. C. Cramer
Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials
Stroke, April 1, 2001; 32(4): 909 - 916.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
L. Belayev, Y. Liu, W. Zhao, R. Busto, and M. D. Ginsberg
Human Albumin Therapy of Acute Ischemic Stroke : Marked Neuroprotective Efficacy at Moderate Doses and With a Broad Therapeutic Window
Stroke, February 1, 2001; 32(2): 553 - 560.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. C. Diener, M. Cortens, G. Ford, J. Grotta, W. Hacke, M. Kaste, P. J. Koudstaal, and T. Wessel
Lubeluzole in Acute Ischemic Stroke Treatment : A Double-Blind Study With an 8-Hour Inclusion Window Comparing a 10-mg Daily Dose of Lubeluzole With Placebo
Stroke, November 1, 2000; 31(11): 2543 - 2551.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. S. Kaplan, T. S. Park, E. R. Gonzales, J. M. Gidday, and J. A. Zivin
Hydroxyethyl Starch Reduces Leukocyte Adherence and Vascular Injury in the Newborn Pig Cerebral Circulation After Asphyxia Editorial Comment
Stroke, September 1, 2000; 31(9): 2218 - 2223.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Berrouschot, H. Barthel, J. Koster, S. Hesse, A. Rossler, W. H. Knapp, and D. Schneider
Extracorporeal Rheopheresis in the Treatment of Acute Ischemic Stroke : A Randomized Pilot Study
Stroke, April 1, 1999; 30(4): 787 - 792.
[Abstract] [Full Text] [PDF]